Treatment of Ulcerative Colitis and Seronegative Inflammatory Spondyloarthritis With Vedolizumab and Tofacitinib

Lee, Joy A.; Magavi, Pooja; Konijeti, Gauree G.

doi:10.1093/ibd/izaa158

Cited by 9 publications

(5 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nine studies totaling 68 patients were treated with a combination of vedolizumab and tofacitinib for the treatment of partially or non-responsive IBD (Tables 2, 3). Several small case reports and case series of vedolizumab and tofacitinib included six UC patients treated for refractory disease and demonstrated 100% clinical improvement without any reported infections [31][32][33][34]. In the case presented by Lee et al, vedolizumab monotherapy was started in a patient not responsive and intolerant to anti-TNF therapy.…”

Section: Vedolizumab and Tofacitinib Combination Therapymentioning

confidence: 99%

“…Tofacitinib 5 mg twice daily was added and achieved steroid-free remission as well as an endoscopically normal colon at six months. Withdrawal of vedolizumab was attempted with re-emergence of symptoms 11 weeks after last vedolizumab infusion, however, remission was restored after re-initiation of vedolizumab as DTT [32].…”

Section: Vedolizumab and Tofacitinib Combination Therapymentioning

confidence: 99%

See 1 more Smart Citation

Efficacy and Safety of Dual Targeted Therapy for Partially or Non-responsive Inflammatory Bowel Disease: A Systematic Review of the Literature

et al. 2023

View full text Add to dashboard Cite

Background Dual targeted therapy (DTT) has emerged as an attractive therapeutic option for select patients with active inflammatory bowel disease (IBD) who are unable to achieve remission with biologic or small molecule monotherapy. We conducted a systematic review of specific DTT combinations in patients with IBD. Methods We conducted a systematic search of MEDLINE, EMBASE, Scopus, CINAHL Complete, Web of Science Core Collection, and Cochrane Library to identify articles related to the use of DTT for the treatment of Crohn Disease (CD) or ulcerative colitis (UC) published before February 2021. Results Twenty-nine studies were identified comprising 288 patients started on DTT for partially or non-responsive IBD. We identified 14 studies with 113 patients receiving anti-tumor necrosis factor (TNF) and anti-integrin therapies (i.e., vedolizumab and natalizumab), 12 studies with 55 patients receiving vedolizumab and ustekinumab, nine studies with 68 patients receiving vedolizumab and tofacitinib, five studies with 24 patients receiving anti-TNF therapy and tofacitinib, six studies with 18 patients receiving anti-TNF therapy and ustekinumab, and three studies with 13 patients receiving ustekinumab and tofacitinib. Conclusion DTT is a promising approach to improve IBD treatment for patients with incomplete responses to targeted monotherapy. Larger prospective clinical studies are needed to confirm these findings as is additional predictive modeling to identify the patient subgroups most likely to require and benefit from this approach. Supplementary Information The online version contains supplementary material available at 10.1007/s10620-023-07837-0.

show abstract

Section: Vedolizumab and Tofacitinib Combination Therapymentioning

confidence: 99%

Section: Vedolizumab and Tofacitinib Combination Therapymentioning

confidence: 99%

Efficacy and Safety of Dual Targeted Therapy for Partially or Non-responsive Inflammatory Bowel Disease: A Systematic Review of the Literature

et al. 2023

View full text Add to dashboard Cite

show abstract

“…In addition, more than 20 case series and reports provide interesting examples of different clinical scenarios45–67 and several retrospective and uncontrolled observations have explored the outcomes of ACT in patients with refractory intestinal disease, concomitant extraintestinal manifestations or IMID (online supplemental table 1).…”

Section: The Current State-of-the-art In Ibdmentioning

confidence: 99%

The future of drug development for inflammatory bowel disease: the need to ACT (advanced combination treatment)

Danese

Solitano

Jairath

et al. 2022

Gut

View full text Add to dashboard Cite

“…Lee, SD et al (17) identified 19 patients treated with Tofacitinib and biologic agents for refractory Crohn's Disease between 2017 and 2019 and discovered that combining Tofacitinib with biologic agents were effective in achieving clinical and endoscopic improvement in some patients with severe, refractory Crohn's Disease. Lee, JA et al (18) presented a case of a patient with ulcerative colitis and seronegative inflammatory spondyloarthritis who achieved remission with the dual therapy of vedolizumab and Tofacitinib. Dolinger MT et al ( 19) collected data from refractory pediatric inflammatory bowel disease patients receiving dual therapy.…”

Section: Introductionmentioning

confidence: 99%

“…Lee, JA et al. ( 18 ) presented a case of a patient with ulcerative colitis and seronegative inflammatory spondyloarthritis who achieved remission with the dual therapy of vedolizumab and Tofacitinib. Dolinger MT et al.…”

Section: Introductionmentioning

confidence: 99%

Case report: JAKi and TNFi dual therapy is a potential treatment strategy for difficult-to-treat rheumatoid arthritis

et al. 2022

View full text Add to dashboard Cite

Rheumatoid arthritis (RA) is a heterogeneous chronic disease. RA patients should start disease modifying anti-rheumatic drugs (DMARDs) therapy immediately after diagnosis. If first-line treatment with conventional synthetic DMARDs does not relieve the disease, biology and targeted synthetic DMARDs are options for patients. Patients can switch to different types of biological and targeted synthetic DMARDs if remission is not achieved. However, for patients with difficult-to-treat RA, achieving disease stabilization after the failure of multiple biological and targeted synthetic DMARDs is a clinical challenge that needs to be addressed. As distinct cytokine pathways, the benefits and challenges of dual therapy are worth discussing. As the most extensively used biologic DMARDs, adalimumab is an anti-tumor necrosis factor monoclonal antibody used to treat RA. Tofacitinib, as a Janus Kinase inhibitor, is an orally administered targeted synthetic DMARDs that involved in the regulation of immune responses by directly or indirectly inhibiting cytokine pathways. This report describes a successful case of a 48-year-old woman with difficult-to-treat RA who treated with Tofacitinib combined with adalimumab. She had been on glucocorticosteroid for a long time, but had persistent joint pain and fatigue. At more than one year of follow-up, her Disease Activity Score for 28-joint counts based on the erythrocyte sedimentation rate (DAS28-ESR) remained in complete remission, and she discontinued her glucocorticosteroid medications. Also, she did not develop a mycobacterial tuberculosis infection, herpes zoster, and new-onset cardiovascular events.

show abstract

Treatment of Ulcerative Colitis and Seronegative Inflammatory Spondyloarthritis With Vedolizumab and Tofacitinib

Abstract: The case report describes the benefits of combination therapy with vedolizumab and tofacitinib in a patient with ulcerative colitis and seronegative inflammatory spondyloarthritis.

Cited by 9 publications

References 4 publications

Efficacy and Safety of Dual Targeted Therapy for Partially or Non-responsive Inflammatory Bowel Disease: A Systematic Review of the Literature

Efficacy and Safety of Dual Targeted Therapy for Partially or Non-responsive Inflammatory Bowel Disease: A Systematic Review of the Literature

The future of drug development for inflammatory bowel disease: the need to ACT (advanced combination treatment)

Case report: JAKi and TNFi dual therapy is a potential treatment strategy for difficult-to-treat rheumatoid arthritis

Contact Info

Product

Resources

About